Histone deacetylases (HDACs): characterization of the classical HDAC family.
暂无分享,去创建一个
A. V. van Kuilenburg | A. V. Van Gennip | H. Caron | Annemieke J M de Ruijter | S. Kemp | A. V. van Gennip
[1] N. Davidson,et al. Role of DNA Methylation and Histone Acetylation in Steroid Receptor Expression in Breast Cancer , 2001, Journal of Mammary Gland Biology and Neoplasia.
[2] A. Wozniak,et al. Chronic Oral Administration of CI-994: A Phase I Study , 2004, Investigational New Drugs.
[3] E. Olson,et al. Association of Class II Histone Deacetylases with Heterochromatin Protein 1: Potential Role for Histone Methylation in Control of Muscle Differentiation , 2002, Molecular and Cellular Biology.
[4] Fred Asselbergs,et al. Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family* , 2002, The Journal of Biological Chemistry.
[5] Daniel Delorme,et al. Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors. , 2002, Journal of medicinal chemistry.
[6] K. Min,et al. Regulation of lifespan by histone deacetylase , 2002, Ageing Research Reviews.
[7] Peter A. Jones,et al. The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.
[8] K. Resing,et al. Phosphatase Inhibition Leads to Histone Deacetylases 1 and 2 Phosphorylation and Disruption of Corepressor Interactions* , 2002, The Journal of Biological Chemistry.
[9] Xiao-Fan Wang,et al. HDAC6 is a microtubule-associated deacetylase , 2002, Nature.
[10] Ioannis Xenarios,et al. Microarray Deacetylation Maps Determine Genome-Wide Functions for Yeast Histone Deacetylases , 2002, Cell.
[11] John J. Andreucci,et al. Composition and Function of AP-1 Transcription Complexes during Muscle Cell Differentiation* , 2002, The Journal of Biological Chemistry.
[12] L. Neckers,et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. , 2002, Journal of the National Cancer Institute.
[13] Y. Ozawa. [Histone deacetylase-targeted anti-leukemia therapy]. , 2002, [Rinsho ketsueki] The Japanese journal of clinical hematology.
[14] A. Caudy,et al. Functional Divergence between Histone Deacetylases in Fission Yeast by Distinct Cellular Localization and In Vivo Specificity , 2002, Molecular and Cellular Biology.
[15] Ricky W. Johnstone,et al. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.
[16] Weidong Wang,et al. Specific targeting and constitutive association of histone deacetylase complexes during transcriptional repression. , 2002, Genes & development.
[17] T. Fojo,et al. Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells. , 2002, Blood.
[18] Wen‐Ming Yang,et al. Functional Domains of Histone Deacetylase-3* , 2002, The Journal of Biological Chemistry.
[19] A. Zetterberg,et al. The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. , 2002, Experimental cell research.
[20] V. Richon,et al. Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] S. Bates,et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] N. Bertos,et al. Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. , 2002, Nucleic acids research.
[23] P. Atadja,et al. Isolation and Characterization of a Novel Class II Histone Deacetylase, HDAC10* , 2002, The Journal of Biological Chemistry.
[24] R. Warrell,et al. Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. , 2002, Blood.
[25] C. Tei,et al. Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells. , 2002, International journal of cancer.
[26] T. Yao,et al. Molecular Cloning and Characterization of a Novel Histone Deacetylase HDAC10* , 2002, The Journal of Biological Chemistry.
[27] K. Helin,et al. The role of p53 and pRB in apoptosis and cancer. , 2002, Current opinion in genetics & development.
[28] H. Kwon,et al. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis , 2002, International journal of cancer.
[29] Manfred Jung,et al. Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. , 2002, Journal of medicinal chemistry.
[30] E. Nicolas,et al. Functional and physical interaction between the histone methyl transferase Suv39H1 and histone deacetylases. , 2002, Nucleic acids research.
[31] R. Evans,et al. Isolation and Characterization of Mammalian HDAC10, a Novel Histone Deacetylase* , 2002, The Journal of Biological Chemistry.
[32] F. Dequiedt,et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. , 2002, Molecular cell.
[33] Ping Zhu,et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.
[34] S. Schreiber,et al. Histone Deacetylase 1 Phosphorylation Promotes Enzymatic Activity and Complex Formation* , 2001, The Journal of Biological Chemistry.
[35] A. Verdel,et al. Mechanism for Nucleocytoplasmic Shuttling of Histone Deacetylase 7* , 2001, The Journal of Biological Chemistry.
[36] R. Marmorstein. Structure of histone deacetylases: insights into substrate recognition and catalysis. , 2001, Structure.
[37] N. Rosen,et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. , 2001, Cancer research.
[38] P. Marks,et al. Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.
[39] G. Bae,et al. Activation of p21WAF1/Cip1 Transcription through Sp1 Sites by Histone Deacetylase Inhibitor Apicidin , 2001, The Journal of Biological Chemistry.
[40] Design and synthesis of a novel class of histone deacetylase inhibitors. , 2001, Bioorganic & medicinal chemistry letters.
[41] D. Lavelle,et al. Histone deacetylase inhibitors increase p21WAF1 and induce apoptosis of human myeloma cell lines independent of decreased IL‐6 receptor expression , 2001, American journal of hematology.
[42] V. Richon,et al. Histone deacetylase inhibitors as new cancer drugs , 2001, Current opinion in oncology.
[43] P. Pandolfi,et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. , 2001, The Journal of clinical investigation.
[44] W. Wilson,et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. , 2001, Blood.
[45] Sandy D. Westerheide,et al. The p65 (RelA) Subunit of NF-κB Interacts with the Histone Deacetylase (HDAC) Corepressors HDAC1 and HDAC2 To Negatively Regulate Gene Expression , 2001, Molecular and Cellular Biology.
[46] J. Herman,et al. Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells , 2001 .
[47] T. Ekström,et al. Differential expression of class I HDACs: roles of cell density and cell cycle. , 2001, International journal of oncology.
[48] E. Olson,et al. Control of muscle development by dueling HATs and HDACs. , 2001, Current opinion in genetics & development.
[49] S. Pavey,et al. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. , 2001, Molecular pharmacology.
[50] F. Dequiedt,et al. Human HDAC7 Histone Deacetylase Activity Is Associated with HDAC3in Vivo * , 2001, The Journal of Biological Chemistry.
[51] M. Guenther,et al. The SMRT and N-CoR Corepressors Are Activating Cofactors for Histone Deacetylase 3 , 2001, Molecular and Cellular Biology.
[52] Richard A. Rifkind,et al. Cloning and characterization of a histone deacetylase, HDAC9 , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[53] E. Bresnick,et al. Histone acetylation beyond promoters: long‐range acetylation patterns in the chromatin world * , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.
[54] T. Heinzel,et al. Histone deacetylase as a therapeutic target , 2001, Trends in Endocrinology & Metabolism.
[55] Ya-Li Yao,et al. Regulation of Transcription Factor YY1 by Acetylation and Deacetylation , 2001, Molecular and Cellular Biology.
[56] E. Miska,et al. Differential localization of HDAC4 orchestrates muscle differentiation. , 2001, Nucleic acids research.
[57] J. Black,et al. Sp1 and krüppel‐like factor family of transcription factors in cell growth regulation and cancer , 2001, Journal of cellular physiology.
[58] L. Grochow,et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[59] M. Grever,et al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[60] E. Nicolas,et al. The histone deacetylase HDAC3 targets RbAp48 to the retinoblastoma protein. , 2001, Nucleic acids research.
[61] Jianqi Yang,et al. Sodium Butyrate Induces Transcription from the Gαi2Gene Promoter through Multiple Sp1 Sites in the Promoter and by Activating the MEK-ERK Signal Transduction Pathway* , 2001, The Journal of Biological Chemistry.
[62] Tae-Hee Han,et al. 14-3-3 associates with and activates the MEF2D transcription factor during muscle cell differentiation , 2001, Nucleic Acids Res..
[63] M. Nishiyama,et al. Histone deacetylase as a new target for cancer chemotherapy , 2001, Cancer Chemotherapy and Pharmacology.
[64] Hui Li,et al. SMRTe Inhibits MEF2C Transcriptional Activation by Targeting HDAC4 and 5 to Nuclear Domains* , 2001, The Journal of Biological Chemistry.
[65] V. Della Pietra,et al. Genes modulated by histone acetylation as new effectors of butyrate activity , 2001, FEBS letters.
[66] Pier Giuseppe Pelicci,et al. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? , 2001, Oncogene.
[67] M. Downes,et al. A Dynamic Role for HDAC7 in MEF2-mediated Muscle Differentiation* , 2001, The Journal of Biological Chemistry.
[68] R. Muschel,et al. Paradoxical effects of trichostatin A: inhibition of NF-Y-associated histone acetyltransferase activity, phosphorylation of hGCN5 and downregulation of cyclin A and B1 mRNA. , 2001, Cancer letters.
[69] P. Marks,et al. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. , 2001, Cancer research.
[70] A. Harel-Bellan,et al. Histone acetylation and disease , 2001, Cellular and Molecular Life Sciences CMLS.
[71] M. Posch,et al. Homo-oligomerisation and nuclear localisation of mouse histone deacetylase 1. , 2001, Journal of molecular biology.
[72] P. Wade. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. , 2001, Human molecular genetics.
[73] R C Coombes,et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[74] A. Verdel,et al. Functional significance of histone deacetylase diversity. , 2001, Current opinion in genetics & development.
[75] C. Cordon-Cardo,et al. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[76] S. Cooper,et al. Revisiting retinoblastoma protein phosphorylation during the mammalian cell cycle , 2001, Cellular and Molecular Life Sciences CMLS.
[77] F. Baas,et al. The Human Transcriptome Map: Clustering of Highly Expressed Genes in Chromosomal Domains , 2001, Science.
[78] P. Pelicci,et al. Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. , 2001, Cancer research.
[79] M. Carducci,et al. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. , 2001, Cancer research.
[80] G. Otterson,et al. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. , 2001, Cancer research.
[81] T. Ekström,et al. The human histone deacetylase family. , 2001, Experimental cell research.
[82] M. Yoshida,et al. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[83] Jianqi Yang,et al. promoter through multiple Sp1 sites in the promoter and by activating the MEK-ERK signal transduction pathway , 2001 .
[84] 小澤 幸泰. Histone deacetylase 3 associates with and represses the transcription factor GATA-2 , 2001 .
[85] H. W. Lee,et al. Activation of p21(WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C. , 2001, The Journal of biological chemistry.
[86] J. Herman,et al. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. , 2001, Cancer research.
[87] N. Bertos,et al. Class II histone deacetylases: structure, function, and regulation. , 2001, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[88] S. Park,et al. 14-3-3tau associates with and activates the MEF2D transcription factor during muscle cell differentiation. , 2001, Nucleic acids research.
[89] G. Bae,et al. Activation of p 21 WAF 1 / Cip 1 Transcription through Sp 1 Sites by Histone Deacetylase Inhibitor Apicidin INVOLVEMENT OF PROTEIN KINASE , 2001 .
[90] P G Pelicci,et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. , 2001, Cancer research.
[91] P. Marks,et al. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. , 2000, Medical and pediatric oncology.
[92] E. Olson,et al. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation , 2000, Nature.
[93] H. W. Lee,et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. , 2000, Cancer research.
[94] I. Adcock,et al. Glucocorticoid Receptor Recruitment of Histone Deacetylase 2 Inhibits Interleukin-1β-Induced Histone H4 Acetylation on Lysines 8 and 12 , 2000, Molecular and Cellular Biology.
[95] R. Evans,et al. Identification of a nuclear domain with deacetylase activity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[96] A. Moon,et al. Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype. , 2000, Cancer letters.
[97] P. Marks,et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[98] J. Clark,et al. Cloning and characterization of a novel human histone deacetylase, HDAC8. , 2000, The Biochemical journal.
[99] K. Imai,et al. Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. , 2000 .
[100] J. Mariadason,et al. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. , 2000, Cancer research.
[101] P. Marks,et al. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.
[102] J. Neefs,et al. Cloning and characterization of human histone deacetylase 8 , 2000, FEBS letters.
[103] Wen‐Ming Yang,et al. Histone Deacetylases Specifically Down-regulate p53-dependent Gene Activation* , 2000, The Journal of Biological Chemistry.
[104] W. D. Cress,et al. Histone deacetylases, transcriptional control, and cancer , 2000, Journal of cellular physiology.
[105] S. Kern,et al. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. , 2000, Cancer research.
[106] James D. Winkler,et al. Cloning and Characterization of a Novel Human Class I Histone Deacetylase That Functions as a Transcription Repressor* , 2000, The Journal of Biological Chemistry.
[107] Hong Sun,et al. Stra13 expression is associated with growth arrest and represses transcription through histone deacetylase (HDAC)-dependent and HDAC-independent mechanisms. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[108] J. Herman,et al. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. , 2000, Trends in genetics : TIG.
[109] J. Galmiche,et al. Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression , 2000, Gut.
[110] T. Naoe,et al. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all‐trans retinoic acid , 2000, British journal of haematology.
[111] P. Marks,et al. Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[112] C. Allis,et al. The language of covalent histone modifications , 2000, Nature.
[113] R. Evans,et al. Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. , 2000, Genes & development.
[114] R. Eisenman,et al. The Myc/Max/Mad network and the transcriptional control of cell behavior. , 2000, Annual review of cell and developmental biology.
[115] P. Marks,et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.
[116] P. Marks,et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. , 1999, Cancer research.
[117] A. Bird,et al. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. , 1999, Genes & development.
[118] H. Huang,et al. Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells. , 1999, Cancer research.
[119] K. Georgopoulos,et al. Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes , 1999, The EMBO journal.
[120] S. Horinouchi,et al. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase , 1999, Oncogene.
[121] T. Tsuruo,et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[122] J. Herman,et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.
[123] P. Pandolfi,et al. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. , 1998, Journal of the National Cancer Institute.
[124] S. Gullans,et al. Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by trichostatin A and butyrate. , 1998, Biochemical and biophysical research communications.
[125] Chi-Wai Wong,et al. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein , 1998, Oncogene.
[126] J. Simons,et al. Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines. , 1998, International journal of oncology.
[127] S. Schreiber,et al. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[128] Tony Kouzarides,et al. Retinoblastoma protein recruits histone deacetylase to repress transcription , 1998, Nature.
[129] C. Glass,et al. A complex containing N-CoR, mSln3 and histone deacetylase mediates transcriptional repression , 1997, nature.
[130] M. Berger,et al. Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo and in vitro. , 1996, European journal of cancer.
[131] C. Van Lint,et al. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. , 1996, Gene expression.
[132] M. Yoshida,et al. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. , 1993, The Journal of biological chemistry.
[133] Histone deacetylase , 1993, FEBS letters.
[134] M. Yoshida,et al. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. , 1990, Journal of Biological Chemistry.
[135] J. Bender,et al. Phase I Trial , 1983 .
[136] H. Stähelin,et al. Cytostatic activity of chlamydocin, a rapidly inactivated cyclic tetrapeptide. , 1974, European journal of cancer.
[137] D. Lorimer,et al. Cloning and characterization of a novel human histone deacetylase , HDAC 8 , 2022 .